THE JOURNAL OF CLINICAL AND APPLIED RESEARCH AND EDUCATION

Diabetes Care

VOLUME 15 NUMBER 8

AUGUST 1992

▶ *Table of contents continued*

American Diabetes Association.

ISSN 0149-5992

Today's hypertensives with new concerns...

THE CARDURA GENERATION

Choose CARDURA: first-line therapy for a new generation of hypertensives.

Choose CARDURA for around-the-clock blood pressure control that doesn't jeopardize blood lipids or blood sugar.[1-3]

CARDURA is well tolerated. In placebo-controlled studies, only three common side effects were reported significantly more often than with placebo: dizziness, somnolence, and fatigue. These were generally mild and transient. Only 2% of patients discontinued therapy due to adverse effects— the same as with placebo. Syncope has been reported, but rarely (<1%).

ONCE-A-DAY

CARDURA®

(doxazosin mesylate) Scored Tablets 1 mg, 2 mg, 4 mg, 8 mg

HYPERTENSION CONTROL FOR A NEW GENERATION.

Please see brief summary of prescribing information on next page.

ONCE-A-DAY

CARDURA®

(doxazosin mesylate) Scored Tablets 1 mg, 2 mg, 4 mg, 8 mg

References: 1. Pickering TG, Hypertension and Lipid Trial Study Group. The use of 24-hour ambulatory monitoring in the assessment of antihypertensive therapy. Presented at the American Academy of Family Physicians 43rd Annual Assembly; September 24-29,1991; Washington, D.C. **2.** The Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study: a randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. *Arch Intern Med.* 1991;151:1413-1423. **3.** Lehtonen A, the Finnish Multicenter Study Group. Lowered levels of serum insulin, glucose, and cholesterol in hypertensive patients during treatment with doxazosin. *Curr Ther Res.* 1990;47:278-284.

CARDURA® (doxazosin mesylate) Tablets
Brief Summary of Prescribing Information

INDICATIONS AND USAGE

CARDURA (doxazosin mesylate) is indicated for the treatment of hypertension. CARDURA may be used alone or in combination with diuretics or beta-adrenergic blocking agents. There is limited experience with CARDURA in combination with angiotensin converting enzyme inhibitors or calcium channel blockers.

CONTRAINDICATIONS

CARDURA is contraindicated in patients with a known sensitivity to quinazolines (e.g. prazosin, terazosin).

WARNINGS

Syncope and "First-dose" Effect:

Doxazosin, like other alpha-adrenergic blocking agents, can cause marked hypotension, especially in the upright position, with syncope and other postural symptoms such as dizziness. Marked orthostatic effects are most common with the first dose but can also occur when there is a dosage increase, or if therapy is interrupted for more than a few days. To decrease the likelihood of excessive hypotension and syncope, it is essential that treatment be initiated with the 1 mg dose. The 2, 4, and 8 mg tablets are not for initial therapy. Dosage should then be adjusted slowly (see DOSAGE AND ADMINISTRATION section) with increases in dose every two weeks. Additional antihypertensive agents should be added with caution. Patients being titrated with doxazosin should be cautioned to avoid situations where injury could result should syncope occur.

In an early investigational study of the safety and tolerance of increasing daily doses of doxazosin in normotensives beginning at 1 mg/day, only 2 of 6 subjects could tolerate more than 2 mg/day without experiencing symptomatic postural hypotension. In another study of 24 healthy normotensive male subjects receiving initial doses of 2 mg/day of doxazosin, seven (29%) of the subjects experienced symptomatic postural hypotension between 0.5 and 6 hours after the first dose necessitating termination of the study. In this study 2 of the normotensive subjects experienced syncope. Subsequent trials in hypertensive patients always began doxazosin dosing at 1 mg/day resulting in a 4% incidence of postural side effects at 1 mg/day with no cases of syncope.

In multiple dose clinical trials involving over 1500 patients with dose titration every one to two weeks, syncope was reported in 0.7% of patients. None of these events occurred at the starting dose of 1 mg and 1.2% (8/664) occurred at 16 mg/day.

If syncope occurs, the patient should be placed in a recumbent position and treated supportively as necessary.

PRECAUTIONS

General

1. Orthostatic Hypotension:

While syncope is the most severe orthostatic effect of CARDURA, other symptoms of lowered blood pressure, such as dizziness, lightheadedness, or vertigo, can occur, especially at initiation of therapy or at the time of dose increases. These were common in clinical trials, occurring in up to 23% of all patients treated and causing discontinuation of therapy in about 2%.

In placebo controlled titration trials orthostatic effects were minimized by beginning therapy at 1 mg per day and titrating every two weeks to 2, 4, or 8 mg per day. There was an increased frequency of orthostatic effects in patients given 8 mg or more, 10%, compared to 5% at 1-4 mg and 3% in the placebo group.

Patients in occupations in which orthostatic hypotension could be dangerous should be treated with particular caution.

If hypotension occurs, the patient should be placed in the supine position and, if this measure is inadequate, volume expansion with intravenous fluids or vasopressor therapy may be used. A transient hypotensive response is not a contraindication to further doses of CARDURA.

2. Impaired liver function:

CARDURA should be administered with caution to patients with evidence of impaired hepatic function or to patients receiving drugs known to influence hepatic metabolism (see CLINICAL PHARMACOLOGY). There is no controlled clinical experience with CARDURA in patients with these conditions.

3. Leukopenia/Neutropenia:

Analysis of hematologic data from patients receiving CARDURA in controlled clinical trials showed that the mean WBC (N=474) and mean neutrophil counts (N=419) were decreased by 2.4% and 1.0% respectively, compared to placebo, a phenomenon seen with other alpha blocking drugs. A search through a data base of 2400 patients revealed 4 in which drug-related neutropenia could not be ruled out. Two had a single low value on the last day of treatment. Two had stable, non-progressive neutrophil counts in the 1000/mm³ range over periods of 20 and 40 weeks. In cases where follow-up was available the WBCs and neutrophil counts returned to normal after discontinuation of CARDURA. No patients became symptomatic as a result of the low WBC or neutrophil counts.

Information for Patients:

Patients should be made aware of the possibility of syncopal and orthostatic symptoms, especially at the initiation of therapy, and urged to avoid driving or hazardous tasks for 24 hours after the first dose, after a dosage increase, and after interruption of therapy when treatment is resumed. They should be cautioned to avoid situations where injury could result should syncope occur during initiation of doxazosin therapy. They should also be advised of the need to sit or lie down when symptoms of lowered blood pressure occur, although these symptoms are not always orthostatic, and to be careful when rising from a sitting or lying position. If dizziness, lightheadedness, or palpitations are bothersome they should be reported to the physician, so that dose adjustment can be considered. Patients should also be told that drowsiness or somnolence can occur with doxazosin, requiring caution in people who must drive or operate heavy machinery.

Drug Interactions:

Most (98%) of plasma doxazosin is protein bound. *In vitro* data in human plasma indicate that CARDURA has no effect on protein binding of digoxin, warfarin, phenytoin or indomethacin. There is no information on the effect of other highly plasma protein bound drugs on doxazosin binding. CARDURA has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics, beta blocking agents, and nonsteroidal anti-inflammatory drugs.

Drug/Laboratory test Interactions:

None known.

Cardiac Toxicity in Animals:

An increased incidence of myocardial necrosis or fibrosis was displayed by Sprague-Dawley rats after 6 months of dietary administration at concentrations calculated to provide 80 mg doxazosin/kg/day and after 12 months of dietary administration at concentrations calculated to provide 40 mg doxazosin/kg/day (150 times the maximum recommended human dose assuming a patient weight of 60 kg). Myocardial fibrosis was observed in both rats and mice treated in the same manner with 40 mg doxazosin/kg/day for 18 months. No cardiotoxicity was observed at lower doses (up to 10 or 20 mg/kg/day, depending on the study) in either species. These lesions were not observed after 12 months of oral dosing in dogs and Wistar rats at maximum doses of 20 mg/kg/day and 100 mg/kg/day, respectively. There is no evidence that similar lesions occur in humans.

Carcinogenesis, Mutagenesis and Impairment of Fertility:

Chronic dietary administration (up to 24 months) of doxazosin mesylate at maximally tolerated concentrations (highest dose 40 mg/kg: about 150 times the maximum recommended human dose of 16 mg/60 kg) revealed no evidence of carcinogenicity in rats. There was also no evidence of carcinogenicity in a similarly conducted study (up to 18 months of dietary administration) in mice. The mouse study, however, was compromised by the failure to use a maximally tolerated dose of doxazosin.

Mutagenicity studies revealed no drug- or metabolite-related effects at either chromosomal or subchromosomal levels.

Studies in rats showed reduced fertility in males treated with doxazosin at oral doses of 20 (but not 5 or 10) mg/kg/day, about 75 times the maximum recommended human dose. This effect was reversible within two weeks of drug withdrawal.

Pregnancy

Teratogenic Effects, Pregnancy Category B. Studies in rabbits and rats at daily oral doses of up to 40 and 20 mg/kg, respectively (150 and 75 times the maximum recommended daily dose of 16 mg, assuming a patient weight of 60 kg), have revealed no evidence of harm to the fetus. The rabbit study, however, was compromised by the failure to use a maximally tolerated dose of doxazosin. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, CARDURA should be used during pregnancy only if clearly needed.

Radioactivity was found to cross the placenta following oral administration of labelled doxazosin to pregnant rats.

Nonteratogenic Effects. In peri-postnatal studies in rats, postnatal development at maternal doses of 40 or 50 mg/kg/day of doxazosin was delayed as evidenced by slower body weight gain and a slightly later appearance of anatomical features and reflexes.

Nursing Mothers

Studies in lactating rats given a single oral dose of 1 mg/kg of [2-^{14}C]-doxazosin indicate that doxazosin accumulates in rat breast milk with a maximum concentration about 20 times greater than the maternal plasma concentration. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when CARDURA is administered to a nursing mother.

Pediatric Use

Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

CARDURA has been administered to approximately 4000 patients, of whom 1679 were included in the clinical development program. In that program, minor adverse effects were frequent, but led to discontinuation of treatment in only 7% of patients. In placebo-controlled studies adverse effects occurred in 49% and 40% of patients in the doxazosin and placebo groups, respectively, and led to discontinuation in 2% of patients in each group. The major reasons for discontinuation were postural effects (2%), edema, malaise/fatigue, and some heart rate disturbance, each about 0.7%.

In controlled clinical trials directly comparing CARDURA to placebo there was no significant difference in the incidence of side effects, except for dizziness (including postural), weight gain, somnolence and fatigue / malaise. Postural effects and edema appeared to be dose related.

The prevalence rates presented below are based on combined data from placebo-controlled studies involving once daily administration of doxazosin at doses ranging from 1-16 mg. Table 1 summarizes those adverse experiences (possibly/probably related) reported for patients in these studies where the prevalence rate in the doxazosin group was at least 0.5% or where the reaction is of particular interest.

TABLE 1
ADVERSE REACTIONS DURING PLACEBO CONTROLLED STUDIES

		DOXAZOSIN (N=339)	PLACEBO (N=336)
CARDIOVASCULAR:	Dizziness	19%	9%
	Vertigo	2%	1%
	Postural Hypotension	0.3%	0%
	Edema	4%	3%
	Palpitation	2%	3%
	Arrhythmia	1%	0%
	Hypotension	1%	0%
	Tachycardia	0.3%	1%
	Peripheral Ischemia	0.3%	0%
SKIN APPENDAGES:	Rash	1%	1%
	Pruritus	1%	1%
MUSCULOSKELETAL:	Arthralgia/Arthritis	1%	0%
	Muscle Weakness	1%	0%
	Myalgia	1%	0%
CENTRAL & PERIPHERAL N.S.:	Headache	14%	16%
	Paresthesia	1%	1%
	Kinetic Disorders	1%	0%
	Ataxia	1%	0%
	Hypertonia	1%	0%
	Muscle Cramps	1%	0%
AUTONOMIC:	Mouth Dry	2%	2%
	Flushing	1%	0%
SPECIAL SENSES:	Vision Abnormal	2%	1%
	Conjunctivitis/Eye Pain	1%	1%
	Tinnitus	1%	0.3%
PSYCHIATRIC:	Somnolence	5%	1%
	Nervousness	2%	2%
	Depression	1%	1%
	Insomnia	1%	1%
	Sexual Dysfunction	2%	1%
GASTROINTESTINAL:	Nausea	3%	4%
	Diarrhea	2%	3%
	Constipation	1%	1%
	Dyspepsia	1%	1%
	Flatulence	1%	1%
	Abdominal Pain	0%	2%
	Vomiting	0%	1%
RESPIRATORY:	Rhinitis	3%	1%
	Dyspnea	1%	1%
	Epistaxis	1%	0%
URINARY:	Polyuria	2%	0%
	Urinary Incontinence	1%	0%
	Micturation Frequency	0%	2%
GENERAL:	Fatigue/Malaise	12%	6%
	Chest Pain	2%	2%
	Asthenia	1%	1%
	Face Edema	1%	0%
	Pain	2%	2%

Additional adverse reactions have been reported, but these are, in general, not distinguishable from symptoms that might have occurred in the absence of exposure to doxazosin. The following adverse reactions occurred with a frequency of between 0.5% and 1%: syncope, hypoesthesia, increased sweating, agitation, increased weight. The following additional adverse reactions were reported by <0.5% of 3960 patients who received doxazosin in controlled or open, short- or long-term clinical studies, including international studies. *Cardiovascular System:* angina pectoris, myocardial infarction, cerebrovascular accident; *Autonomic Nervous System:* pallor; *Metabolic:* thirst, gout, hypokalemia; *Hematopoietic:* lymphadenopathy, purpura; *Reproductive System:* breast pain; *Skin Disorders:* alopecia, dry skin, eczema; *Central Nervous System:* paresis, tremor, twitching, confusion, migraine, impaired concentration; *Psychiatric:* paroniria, amnesia, emotional lability, abnormal thinking, depersonalization; *Special Senses:* parosmia, earache, taste perversion, photophobia, abnormal lacrimation; *Gastrointestinal System:* increased appetite, anorexia, fecal incontinence, gastroenteritis; *Respiratory System:* bronchospasm, sinusitis, coughing, pharyngitis; *Urinary System:* renal calculus; *General Body System:* hot flushes, back pain, infection, fever/rigors, decreased weight, influenza-like symptoms.

CARDURA has not been associated with any clinically significant changes in routine biochemical tests. No clinically relevant adverse effects were noted on serum potassium, serum glucose, uric acid, blood urea nitrogen, creatinine or liver function tests. CARDURA has been associated with decreases in white blood cell counts (See Precautions).

OVERDOSAGE

No data are available in regard to overdosage in humans.

The oral LD_{50} of doxazosin is greater than 1000 mg/kg in mice and rats. The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of fluid. As doxazosin is highly protein bound, dialysis would not be indicated.

DOSAGE AND ADMINISTRATION

DOSAGE MUST BE INDIVIDUALIZED. The initial dosage of CARDURA in hypertensive patients is 1 mg given once daily. This starting dose is intended to minimize the frequency of postural hypotension and first dose syncope associated with CARDURA. Postural effects are most likely to occur between 2 and 6 hours after a dose. Therefore blood pressure measurements should be taken during this time period after the first dose and with each increase in dose. Depending on the individual patient's standing blood pressure response (based on measurements taken at 2-6 hours postdose and 24 hours postdose), dosage may then be increased to 2 mg and thereafter if necessary to 4 mg, 8 mg and 16 mg to achieve the desired reduction in blood pressure. **Increases in dose beyond 4 mg increase the likelihood of excessive postural effects including syncope, postural dizziness/vertigo, postural hypotension. At a titrated dose of 16 mg once daily the frequency of postural effects is about 12% compared to 3% for placebo.**

HOW SUPPLIED

CARDURA (doxazosin mesylate) is available as colored tablets for oral administration. Each tablet contains doxazosin mesylate equivalent to 1 mg (white), 2 mg (yellow), 4 mg (orange) or 8 mg (green) of the active constituent, doxazosin.

CARDURA® TABLETS are available as 1 mg (white), 2 mg (yellow), 4 mg (orange) and 8 mg (green) scored tablets.

Bottles of 100: 1 mg (NDC 0049-2750-66), 2 mg (NDC 0049-2760-66), 4 mg (NDC 0049-2770-66), 8 mg (NDC 0049-2780-66)

Recommended Storage: Store below 86°F(30°C).

CAUTION: Federal law prohibits dispensing without prescription.

65-4538-00-0 Issued Nov 1990

Pfizer Roerig

THE JOURNAL OF CLINICAL AND APPLIED RESEARCH AND EDUCATION

VOLUME 15 NUMBER 8

Diabetes Care

Diabetes Care publishes original articles and reviews of human and clinical research intended to increase knowledge, stimulate research, and promote better management of people with diabetes mellitus. Emphasis is on human studies reporting on the pathophysiology and treatment of diabetes and its complications; genetics; epidemiology; psychosocial adaptation; education; and the development, validation, and application of accepted and new therapies. Topics covered are of interest to clinically oriented physicians, researchers, epidemiologists, psychologists, diabetes educators, and other professionals.

All manuscripts and other editorial correspondence should be sent by first class mail to Allan L. Drash, MD, Editor, *Diabetes Care*, Children's Hospital, Rangos Research Center, 3705 Fifth Avenue, Pittsburgh, PA 15213. Manuscripts and correspondence regarding review articles should be sent to Ralph A. DeFronzo, MD, Review Editor, *Diabetes Care*, Department of Medicine, Division of Diabetes, UT-HSCSA, 7703 Floyd Curl Drive, San Antonio, TX 78284.

Diabetes Care publishes only original material. When submitting a manuscript, authors must state in their transmittal letter that the material has not been previously published or is not currently being submitted to another journal.

Manuscripts should be prepared in accord with the requirements specified in the document "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," *Annals of Internal Medicine* 96: 766–71, 1982. An "Instructions for Authors" page containing specifications for manuscript preparation appears quarterly beginning with the January issue of each volume.

All material published in *Diabetes Care* is copyrighted by the American Diabetes Association, Inc. All manuscripts submitted to *Diabetes Care* must include a transmittal letter stating the following before they will be considered for publication. "In consideration of ADA reviewing my (our) submission, the undersigned author(s) transfers, assigns, or otherwise conveys all copyright ownership to ADA in the event the work is published." Permission to reproduce copyrighted material from *Diabetes Care* will be granted for limited, noncommercial purposes. Permission requests should be addressed to the Permissions Editor, ADA, 1660 Duke St., Alexandria, VA 22314 and should be accompanied by a letter of permission from the senior author of the article.

Diabetes Care (ISSN 0149-5992) is published monthly by the American Diabetes Association, Inc., 1660 Duke Street, Alexandria, VA 22314. The annual subscription rate is $75 for individuals in the U.S. and Canada. Professional Membership dues include $35 designated for *Diabetes Care*. The annual rate for all foreign subscriptions, excluding Canada, is $95. The fee for individual copies is $8 in the U.S. and Canada and $10 in all other countries. Second class postage paid at Alexandria, Virginia 22314, and at additional mailing offices. POSTMASTER: Send change of address to *Diabetes Care*, American Diabetes Association, Inc., P.O. Box 2055, Harlan, IA 51593-0238.

Diabetes Care is listed in Science Citation Index, Current Contests/Life Sciences, Current Contents/Clinical Medicine, SCISEARCH, ISI/BIOMED databases, and Automatic Subject Citation Alert. *Diabetes Care* is available online on BRS Colleague. For more information call 800-468-0908. It is also available in machine-readable format from University Microfilms International. *Diabetes Care* is printed on acid-free paper starting with Vol. 11(1), 1988.

American Diabetes Association.

Original Articles—Continued

Short Reports

Supplement 3: Proceedings of a Consensus Development Conference on Standardized Measures in Diabetic Neuropathy

Acceptance of Manuscripts on Diskette

Diabetes Care welcomes the submission of manuscripts on computer diskettes beginning with the January 1992 issue. The text stored on diskettes, will be used directly for typesetting, which will improve the efficiency and speed of journal production.

Authors should submit diskettes with the final version of their manuscripts, along with the typed revised manuscript. (Do not send diskettes with the initial submission.) All diskettes must be accompanied by 3 accurate double-spaced paper copies of the manuscript.

Either 3.5 or 5.25-inch diskettes can be used, and any major word processing program is acceptable. Diskettes may be produced on IBM, IBM-compatible, Apple, or Wang computers.

Diskettes must be labeled with the following information: 1) author's name, 2) article title, and 3) software and hardware used. Detailed instructions for diskette preparation and submission appear in the instructions for author's guidelines in the first issue of every volume.

Our monitoring system automatically corrects for the difference.

Because no two diabetics are alike, we've designed the CheckMate™ Blood Glucose Monitoring System to help prevent inaccuracies and errors—that even the most careful person could make.

Our system *automatically* calibrates itself with each new test strip and corrects each reading for temperature and hematocrit. And our individually wrapped strips require no blotting, wiping, or timing.

The CheckMate has a built-in memory that provides an accurate and verifiable record of recent test results. It even has alarms that can remind your patients when it's time to test, and that signal if the sample size is inadequate or if they happen to make an error. And CheckMate is the only system with an integrated lancing device and Lifetime Warranty.

But one of the most important features to your patients will be its compact size. The all-in-one system slips easily into a pocket or purse, so your patients may use it more often. And our $75 mail-in rebate offer makes it easy to afford, as well.

To learn more about CheckMate, the monitoring system to recommend for *all* types of diabetics, call our Customer Support Center at **1-800-525-6718**.

CheckMate

Blood Glucose Monitoring System

JUNE 20-23, 1992

American Diabetes Association

HIGHLIGHTS OF THE 52ND ANNUAL MEETING

These audiotapes are the **'Highlights' of the 52nd Annual Meeting** in San Antonio, TX. Hear the "LIVE" presentations delivered by the professionals and receive important information you don't want to miss. ORDER TODAY!! You may purchase the complete set, or individual audiotapes of your choice. Call our toll-free number listed below, and ask for program number AE195. Mastercard, Visa, and American Express credit cards are accepted. Additional charge for shipping and handling. All ship orders must be accompanied by payment in full. Please allow 3 to 4 weeks for delivery. InfoMedix is not responsible for any speaker's or registrant's statements, materials, acts, or omissions. All Sales are Final.

PROFESSIONAL SECTION COUNCIL PROGRAMS

AE195-1AB $20.00 (2 tapes) — **Diabetes in Pregnancy,** Macro and Microvascular Disease Complicating Pregnancy

AE195-4ABC $30.00 (3 tapes) — **Foot Care,** Therapeutic Strategies for Management of the Charcot Foot

AE195-5ABC $30.00 (3 tapes) — **Health Care Delivery and Public Health,** Diabetic Renal Disease: Epidemiology, Clinical Advances, and Cost Considerations

AE195-9AB $20.00 (2 tapes) — **Complications,** New Developments in the Pharmacology of Diabetic Complications

AE195-14AB $20.00 (2 tapes) — **Gestational Diabetes**

AE195-15AB $20.00 (2 tapes) — **Cell Biology of Insulin Production and Secretion**

AE195-16AB $20.00 (2 tapes) — **Lipids and Obesity**

AE195-20 $10.00 — **PRESIDENT'S ADDRESS:** ***The Winds of Change,*** Jay S. Skyler; **BANTING LECTURE:** ***On the Honey Disease: Dialogue With Socrates,*** Gian Franco Bottazzo

AE195-24AB $20.00 (2 tapes) — **Practical Aspects of Exercise Therapy for Diabetes**

AE195-25AB $20.00 (2 tapes) — **New Technologies in Diabetes Therapy**

AE195-29 $10.00 — **LILLY LECTURE:** ***Mechanisms of Insulin Resistance: Lessons From Patients With Mutations in the Insulin Receptor Gene,*** Simeon I. Taylor

AE195-30AB $20.00 (2 tapes) — **Predicting and Preventing IDDM**

Buy the Highlight Set AE195 (24 tapes) FOR ONLY.....$189.00

YOU SAVE.....$51.00

Set price includes the vinyl audiotape storage albums. Price does not include the shipping and handling, or CA sales tax.

InfoMedix

12800 Garden Grove Boulevard • Suite F • Garden Grove, California 92643

MasterCard VISA AMERICAN EXPRESS

1-800-367-9286 (USA/CANADA) **714-530-3454 (INTERNATIONAL)**

point. counter point.

Glucolet® 2

Automatic Lancing Device

WITH UNIQUE FINGERSTIX™ LANCET PROTECTION

Today even taking a fingerstick blood sample can be risky business. To counter the danger of an accidental needlestick injury, Glucolet® 2 features the unique protection of Fingerstix™ Lancet.

Lancet is encased in a rigid, *disposable* endcap to eliminate the need for loading and recapping single lancets, and to keep the lancet needle recessed both *before and after* you take your patient's blood sample.

Glucolet 2 offers you a simple, quick, and economical way to safely obtain blood samples.

For more information about Glucolet 2 and the other diabetes management products from Miles Inc, contact your Diagnostics Division Sales Representative.

Disposable Fingerstix™ Lancet

Making diabetes easier, and safer, to manage

MILES

Diagnostics Division

Miles Inc.
Elkhart, IN 46515

Lead a diabetes support group with the newest resource from the American Diabetes Association.



This complete guide for health-care professionals presents a step-by-step approach to planning and conducting support groups for young adults with type I diabetes. Session plans cover everything from recruitment and screening of participants to the final wrap-up and group evaluation. This manual also provides questionnaires, exercises, and fact sheets for use as handouts to participants.

The following topics are covered:

- Managing Sick Days
- Insulin and Insulin Injection Techniques
- Sexuality and Pregnancy
- Aerobic Exercise
- Managing Stress
- Insulin Reactions
- Psychological Issues
- Complications
- New Developments
- Alcohol and Diabetes
- Employment Discrimination and Other Legal Issues

Diabetes Support Groups for Young Adults: A Facilitator's Manual

I would like to order the newest resource from the American Diabetes Association. Please send me:

___ copies of *Diabetes Support Groups for Young Adults: A Facilitator's Manual.* #PEDSGYA
ADA Members: $14.80, Nonmembers: $16.45 $_____
SUBTOTAL (VA residents add 4.5% state sales tax) $_____
Add Shipping & Handling (see chart) $_____
TOTAL $_____

NAME _____

ADDRESS _____

CITY _____ STATE _____ ZIP _____

Make your check or money order payable to: American Diabetes Association. *Mail to:* American Diabetes Association, 1970 Chain Bridge Road, McLean, VA 22109-0592.

Shipping & Handling Chart
(calculate using the total cost of publications)

up to $5.00	$1.75
$5.01-$10.00	$3.00
$10.01-$25.00	$4.50
$25.01-$50.00	$5.50
over $50.00	10% of order

Allow 6-8 weeks for domestic delivery. Add $3.00 to shipping & handling for each additional "ship to" address. Add $15.00 to shipping & handling for air shipped orders outside the U.S. Prices subject to change without notice.

American Diabetes Association.

HURRY! Order your copy today.

PC89201


In NIDDM,
when diet alone fails,
Glucotrol
spells...
Control
Glucotrol®
(glipizide) 5-mg and 10-mg Scored Tablets
When diet alone fails in non-insulin-dependent diabetes mellitus
Please see brief summary of GLUCOTROL® (glipizide) prescribing information on next page.



Brief Summary of Prescribing Information

INDICATIONS AND USAGE: GLUCOTROL is indicated as an adjunct to diet for the control of hyperglycemia in patients with non-insulin-dependent diabetes mellitus (NIDDM, type II) after an adequate trial of dietary therapy has proved unsatisfactory.

CONTRAINDICATIONS: GLUCOTROL is contraindicated in patients with known hypersensitivity to the drug or with diabetic ketoacidosis, with or without coma, which should be treated with insulin.

SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY: The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (*Diabetes*, 19, supp. 2:747-830, 1970). UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2½ times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of GLUCOTROL and of alternative modes of therapy. Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

PRECAUTIONS: ***Renal and Hepatic Disease:*** *The metabolism and excretion of* GLUCOTROL *may be slowed in* patients with impaired renal and/or hepatic function. Hypoglycemia may be prolonged in such patients should it occur.

Hypoglycemia: All sulfonylureas are capable of producing severe hypoglycemia. Proper patient selection, dosage, and instructions are important to avoid hypoglycemia. Renal or hepatic insufficiency may increase the risk of hypoglycemic reactions. Elderly, debilitated or malnourished patients and those with adrenal or pituitary insufficiency are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly or people taking beta-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used.

Loss of Control of Blood Glucose: A loss of control may occur in diabetic patients exposed to stress such as fever, trauma, infection, or surgery. It may then be necessary to discontinue GLUCOTROL and administer insulin.

Laboratory Tests: Blood and urine glucose should be monitored periodically. Measurement of glycosylated hemoglobin may be useful.

Information for Patients: Patients should be informed of the potential risks and advantages of GLUCOTROL, of alternative modes of therapy, as well as the importance of adhering to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure should also be explained.

Drug Interactions: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. *In vitro* studies indicate that GLUCOTROL binds differently than tolbutamide and does not interact with salicylate or dicumarol. However, caution must be exercised in extrapolating these findings to the clinical situation. Certain drugs tend to produce hyperglycemia and may lead to loss of control including the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known.

Carcinogenesis, Mutagenesis, Impairment of Fertility: A 20-month study in rats and an 18-month study in mice at doses up to 75 times the maximum human dose revealed no evidence of drug-related carcinogenicity. Bacterial and *in vivo* mutagenicity tests were uniformly negative. Studies in rats of both sexes at doses up to 75 times the human dose showed no effects on fertility.

Pregnancy: Pregnancy Category C: GLUCOTROL (glipizide) was found to be mildly fetotoxic in rat reproductive studies at all dose levels (5-50 mg/kg). This fetotoxicity has been similarly noted with other sulfonylureas, such as tolbutamide ar tolazamide. The effect is perinatal and believed to be directly related to the pharmacologic (hypoglycemic) action GLUCOTROL. In studies in rats and rabbits no teratogenic effects were found. There are no adequate and well-controlle studies in pregnant women. GLUCOTROL should be used during pregnancy only if the potential benefit justifies the potenti risk to the fetus.

Because recent information suggests that abnormal blood glucose levels during pregnancy are associated with a highe incidence of congenital abnormalities, many experts recommend that insulin be used during pregnancy to maintain bloo glucose levels as close to normal as possible.

Nonteratogenic Effects: Prolonged severe hypoglycemia has been reported in neonates born to mothers who wer receiving a sulfonylurea drug at the time of delivery. This has been reported more frequently with the use of agents wit prolonged half-lives. GLUCOTROL should be discontinued at least one month before the expected delivery date.

Nursing Mothers: Since some sulfonylurea drugs are known to be excreted in human milk insulin therapy should b considered if nursing is to be continued.

Pediatric Use: Safety and effectiveness in children have not been established.

ADVERSE REACTIONS: In controlled studies, the frequency of serious adverse reactions reported was very low. Of 702 patients, 11.8% reported adverse reactions and in only 1.5% was GLUCOTROL discontinued.

Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections.

Gastrointestinal: Gastrointestinal disturbances, the most common, were reported with the following approximate incidence: nausea and diarrhea, one in 70; constipation and gastralgia, one in 100. They appear to be dose-related and may disappear on division or reduction of dosage. Cholestatic jaundice may occur rarely with sulfonylureas: GLUCOTROL should be discontinued if this occurs.

Dermatologic: Allergic skin reactions including erythema, morbilliform or maculopapular eruptions, urticaria, pruritus, and eczema have been reported in about one in 70 patients. These may be transient and may disappear despite continued use of GLUCOTROL; if skin reactions persist, the drug should be discontinued. Porphyria cutanea tarda and photosensitivity *reactions have been reported with sulfonylureas.*

Hematologic: Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia have been reported with sulfonylureas.

Metabolic: Hepatic porphyria and disulfiram-like alcohol reactions have been reported with sulfonylureas. Clinical experience to date has shown that GLUCOTROL has an extremely low incidence of disulfiram-like reactions.

Endocrine Reactions: Cases of hyponatremia and the syndrome of inappropriate antidiuretic hormone (SIADH) secretion have been reported with this and other sulfonylureas.

Miscellaneous: Dizziness, drowsiness, and headache have each been reported in about one in fifty patients treated with GLUCOTROL. They are usually transient and seldom require discontinuance of therapy.

OVERDOSAGE: Overdosage of sulfonylureas including GLUCOTROL can produce hypoglycemia. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours since hypoglycemia may recur after apparent clinical recovery. Clearance of GLUCOTROL from plasma would be prolonged in persons with liver disease. Because of the extensive protein binding of GLUCOTROL, dialysis is unlikely to be of benefit.

DOSAGE AND ADMINISTRATION: There is no fixed dosage regimen for the management of diabetes mellitus with GLUCOTROL; in general, it should be given approximately 30 minutes before a meal to achieve the greatest reduction in postprandial hyperglycemia.

Initial Dose: The recommended starting dose is 5 mg before breakfast. Geriatric patients or those with liver disease may be started on 2.5 mg. Dosage adjustments should ordinarily be in increments of 2.5–5 mg, as determined by blood glucose response. At least several days should elapse between titration steps.

Maximum Dose: The maximum recommended total daily dose is 40 mg.

Maintenance: Some patients may be effectively controlled on a once-a-day regimen, while others show better response with divided dosing. Total daily doses above 15 mg should ordinarily be divided.

HOW SUPPLIED: GLUCOTROL tablets are white, dye-free, scored, diamond-shaped, and imprinted as follows:

5 mg—Pfizer 411; 10 mg—Pfizer 412.

5 mg Bottles: 100's (NDC 0049-4110-66); 500's (NDC 0049-4110-73); Unit Dose 100's (NDC 0049-4110-41)

10 mg Bottles: 100's (NDC 0049-4120-66); 500's (NDC 0049-4120-73); Unit Dose 100's (NDC 0049-4120-41)

CAUTION: Federal law prohibits dispensing without prescription.

More detailed professional information available on request.

Pfizer Roerig

Revised August 1990

MediSense Sensors. The Benefits Are Obvious. The Choice Is Simple.

Now They're Also 33% Faster.



When we first introduced our exclusive BioSensor technology, the Pen™ and Companion™ sensors quickly became the fastest testing—and one of the fastest growing—blood glucose monitors available.

Now MediSense introduces the second generation Pen™ 2 and Companion™ 2 sensors, with new Sensor Electrodes (strips). Faster, more convenient, and more user-friendly than ever.

AS ALWAYS, COMPLIANCE IS THE KEY TO BETTER HEALTH.

Frequent blood glucose testing helps patients manage their diabetes better. And no one makes testing easier than MediSense.

Patients simply insert our patented Sensor Electrode into the sensor, apply a small drop of blood to the target area, and see accurate results in record time—now just 20 seconds.

There's no need to wipe or blot, saving time and reducing technique errors. No blood ever enters the sensor, eliminating the need for cleaning and the possibility of cross-contamination between samples. And calibration is a simple one-step process.

NOW THE BEST IS EVEN BETTER.

Today, after years of research, testing, and refinement, MediSense can offer patients with diabetes even more:

For *increased ease of use,* the sensor starts automatically as soon as a small blood drop is applied to the Sensor Electrode. This eliminates the need for timing or "button-pushing" and further helps to reduce technique errors.

For *even faster test results,* we reduced the testing time from 30 seconds to *20 seconds,* making the quickest test on the market even quicker.

For *increased flexibility,* our assay reading range has been expanded to 20–600 mg/dL. And an added control feature compensates for temperature variances and eliminates interferences from uric acid and other substances in the blood.

NOTHING IS MORE CONVENIENT. EASY TO TEACH, EASY TO LEARN.

Only our sensors are so easy to learn (and teach), so fast to use, so simple to maintain, and so convenient to carry. And no other system offers a better combination of accuracy, speed, and convenience, with:

- The two smallest monitors available: the ingeniously designed Pen 2 and the credit-card sized Companion 2.
- Individually foil-wrapped, easily opened Sensor Electrodes, in packages of 25 and 50.

MEDISENSE SENSORS. THE BENEFITS ARE OBVIOUS. THE CHOICE IS SIMPLE.

For more information on the Pen 2 and Companion 2 Blood Glucose System, please call 1-800-537-3575.

No monitors are as discreet or test faster than MediSense Pen 2 and Companion 2 Sensors.

MEDISENSE

Sensors for a better life.



Actual size

*100-count size available in early 1991. Cambridge, MA 02139

The world's leading diabetes experts just wrote the only therapy manual you'll ever need.

Imagine not having to wade through volume after volume of diabetes therapy textbooks that consume too much of your time. Or having the expertise of more than 50 diabetes professionals at your fingertips in one new publication.

Well, the world's leading diabetes experts just wrote the only therapy manual you'll ever need. And it's easy to use!



Therapy for Diabetes Mellitus and Related Disorders has just been published by the American Diabetes Association and is the authoritative guide to diabetes therapy. It's a "how to" reference manual filled with all the information you need to provide the best care for your patients. Yet each of the 49 chapters average just seven pages, so you'll be able to digest the latest in treatment and therapy in minutes.

You'll learn about:

- The latest drugs for treating diabetes, including sulfonylureas, metformin, and alpha-glucosidase inhibitors
- Genetic counseling for type I diabetes
- Treating diabetic nerve, eye, and kidney disease
- Controlling blood lipid abnormalities in diabetic patients
- Managing diabetic ketoacidosis and hyperglycemic hyperosmolar coma
- Much, much more!

Therapy for Diabetes Mellitus is also filled with more than 170 charts and tables, making each chapter easier to read and understand. Also, the manual's pocket-sized format will allow you to carry it with you for quick reference whenever necessary.

So order your copy of *Therapy for Diabetes Mellitus and Related Disorders* today. And put the most comprehensive and easy-to-use therapy manual in your pocket.

Yes! Please send me _____ copies of *Therapy for Diabetes Mellitus and Related Disorders* at $22.45 for members or $24.95 for nonmembers. I will be sure to add shipping and handling using the chart below.

Publication Total $_____
Virginia Residents Add 4.5% sales tax $_____
Orders outside the U.S., please add $15 for each airmail shipment $_____
Add shipping & handling (use chart) $_____
GRAND TOTAL $_____

Shipping & Handling Chart

Up to $5.00 ..... add $1.75	$25.01-$50.00 ..... add $5.50
$5.01-$10.00 ..... add $3.00	over $50.00 ..... add 10% of order
$10.01-$25.00 ..... add $4.50	

Name _____

Address _____

City _____ State _____ Zip _____

PC79201

Send your check or money order payable to:

American Diabetes Association®
1970 Chain Bridge Road
McLean, VA 22109-0592

Allow 6-8 weeks for delivery. Add $3.00 to shipping & handling for each additional shipping address. Foreign orders must be paid in U.S. funds, drawn on a U.S. bank. Prices subject to change without notice.

Testing 1-2-3.



Press power, insert strip.



Apply sample. No wiping. No timing.

Accurate results in 45 seconds.

It's that simple. That accurate. And that easy for patients to comply. Because ONE TOUCH® II utilizes the same no-wipe technology proven accurate in clinical studies. In fact, the ONE TOUCH brand is the no-wipe meter recommended most by diabetes specialists and educators. Used by more hospitals. And backed with 24-hour support and service. No wonder the ONE TOUCH II Blood Glucose Meter is fast becoming the meter of choice in its own right. Call your LifeScan Professional Representative, or 1 800 227-8862. We'll put you in touch with fast, accurate, and simple testing. You can count on it.

Accuracy Made Simple.

LIFESCAN INC.

a Johnson & Johnson company

Presenting a diabetes education system that's as unique as the patients who use it.



"Touch Screen" technology lets patients tailor the program to fit their condition.

Every diabetes patient is different. And now there's an educational program that addresses those differences. It's called *About Your Diabetes*™ — an interactive, touch screen system that can be customized for each patient's condition through a series of simple questions. So only relevant information is presented.

It Takes Less Time To Learn More

The personalized *About Your Diabetes* program is fun and easy to use for patients of all ages and literacy levels. With full-motion video, colorful graphics, plus on-screen and audio prompts, patients are more likely to pay attention. As a result, they learn faster and remember more. An easy comprehension test helps ensure that everything is understood.

Quality Of Care And Efficiency Are Enhanced

When patients are actively involved in learning how to manage their disease, they realize how important it is to comply with the treatment plan you provide. And that can help prevent acute problems. Also, because you can feel confident about the accurate, consistent information *About Your Diabetes* delivers, you can be more productive elsewhere in the office.

No Other System Compares

About Your Diabetes is a one-of-a-kind education system that offers all kinds of benefits to both you and your patients. To learn more about it, call **1-800-227-8772, ext. 884** today and ask for the Marketing Department.

USP DI VISUALIZED
ABOUT YOUR DIABETES™
A Comprehensive Patient Education System

USP SINCE 1820

American Diabetes Association.

ADVANCE YOUR DIABETES MANAGEMENT...

RoTAG™ FRUCTOSAMINE ASSAY

RoTAG is a rapid "time averaged glucose" assay for fructosamine (glycated protein), which constitutes an important step forward in the reliability, accuracy, convenience and cost-effectiveness of diabetes management.

Fructosamine serves as a "blood glucose memory," providing previously inaccessible information on average glucose levels for the preceding one to three weeks. For this reason, RoTAG is especially useful in monitoring gestational diabetes, as well as Type I and Type II diabetes.

A solution to the diagnostic dilemma

Diabetes is typically monitored using glucose and glycated hemoglobin (HbA_{1c}) tests. A glucose assay can be performed during a patient visit, yet the test only represents diabetic control at that time. Glycated hemoglobin results reflect six to eight weeks of clinical history, yet testing complexities can delay results.

When a normal glucose result is contrasted with an abnormal glycated hemoglobin result, the physician faces a diagnostic dilemma: Should therapy be adjusted, or should control be presumed and reinforced based on the glucose result? Normal fluctuations in glucose add risk to the latter course, often resulting in patient call-backs and repeat testing for diagnostic confirmation. ***With the availability of rapid results measuring a clinically significant timeframe, RoTAG provides a solution to this diagnostic dilemma.***

Correlates well with other monitoring methods

RoTAG correlates well with fasting glucose and glycated hemoglobin, while it offers clear advantages: RoTAG provides a more immediate view of patient status than glycated hemoglobin, and it is not subject to the potential interferences associated with these tests. RoTAG may also be more reliable than glucose tests due to constant glucose fluctuations, which may be confused with changes in diabetic control.

Convenience at low cost

RoTAG can be performed on a random sample in just minutes, which means RoTAG can be performed routinely in virtually any laboratory. RoTAG is optimized for economy and performance on COBAS® instruments and can be adapted to most automated analyzers.

Appropriate for routine monitoring

Recent studies emphasize the need for consistent glucose control to reduce the risk of diabetic complications. Now RoTAG results can be used with confidence to optimize the therapeutic regimen and the frequency of follow-up and counseling.

Guidelines for Interpretation

Glucose	RoTAG	HbA_{1c}	Interpretation
—	—	—	Normal or controlled diabetic
^	^	—	Out of control within the past three weeks
^	^	^	Newly diagnosed or uncontrolled diabetic
—	—	^	Recently returned to control
—	^	^	Out of control over the past one to eight weeks

— Normal ^ Elevated

Roche RoTAG provides a rapid, sensitive, convenient and cost-effective method for routine assessment of blood glucose control—an important advance in diabetes management.

To advance your diabetes management, call 1-800-526-1247 or write:

Roche Diagnostic Systems
ROCHE a subsidiary of Hoffmann-La Roche Inc.

Roche Diagnostic Systems, Inc
One Sunset Avenue
Montclair, New Jersey 07042-5199

Mark Your Calendar Now!

40TH *Annual Postgraduate Course*



SAN FRANCISCO FAIRMONT
JANUARY 22 - 24, 1993
SAN FRANCISCO, CALIFORNIA

FOR THE 1993 ADA POSTGRADUATE COURSE
JANUARY 22-24, 1993
SAN FRANCISCO, CALIFORNIA

Sessions include:

- ▲ Neuropathy
- ▲ Unusual Subsets of Diabetes
- ▲ Therapies Just Around the Corner
- ▲ Intensive Insulin Therapy Update
- ▲ Obesity
- ▲ Education Strategies for Various Ethnic Populations

FOR MORE INFORMATION, CALL
1-800-ADA-3472, EXT. 330

American Diabetes Association.

Last week, all your patients with diabetes...

never missed a blood glucose reading...

always ate what they should...

and exercised every day.

Right?

Well, maybe not quite. But now you can help tell the difference, because the GLUCOMETER® M+ Diabetes Care System lets you track and verify virtually all aspects of your patients' diabetes treatment programs.

A meter and logbook combined, the GLUCOMETER M+ System tracks blood glucose readings, insulin dosage (and the type of insulin used), changes in diet and exercise, pre- and post-meal blood glucose levels, diabetes-related symptoms and special events.

GLUCOFILM® Test Strip technology assures accurate performance. Step-by-step prompts on the display make it easy for your patients to use.

In addition, with the GLUCOFACTS™+ Data Printer or GLUCOFACTS+ Diabetes Management System software, it's simple to analyze the results. Use the results to educate and motivate your patients to do their best.

After all, no one's perfect. But the GLUCOMETER M+ System is perfect for all those patients whose diabetes control should be second to none.

Write us at the address below, or contact your Miles Inc., Diagnostics Division representative for a free demonstration.

The **Glucometer M+**
Diabetes Care System

MILES

Miles Inc.
Diagnostics Division
P.O. Box 70
Elkhart, IN 46515

From the Next Generation of rDNA Technology

NOVOLIN® 70/30

Novo Nordisk

Combining Control and Confidence

When it comes to glycemic CONTROL, the ideal insulin response is a natural one. NOVOLIN® 70/30 has been formulated to provide rapid onset with sustained duration for a more natural insulin profile than NPH alone.



When it comes to CONFIDENCE, you look for safety, accuracy, and convenience. NOVOLIN® 70/30 eliminates measuring and mixing errors and may improve patient adherence through a simple B.I.D. dosing regimen.

NOVOLIN® 70/30

Human Insulin
(recombinant DNA origin)

Combining Control and Confidence

For more information, call ***1-800-727-6500.***

WARNING: ANY CHANGE IN INSULIN SHOULD BE MADE CAUTIOUSLY AND ONLY UNDER MEDICAL SUPERVISION.

205-62 May 1992 Printed in U.S.A.